
Tapering off Paxil (paroxetine) usually takes 6 months to 2 years, not the 2 to 4 weeks most prescribers suggest. Paroxetine has the shortest half-life of any SSRI at roughly 21 hours, no active metabolite, and nonlinear pharmacokinetics at low doses, which is why it produces the highest rate of withdrawal reactions in its class. The safest approach is reducing by about 10% of your current dose every 4 weeks, holding longer whenever symptoms appear.
That is the short answer. What follows is why paroxetine behaves this way, what withdrawal actually looks like week by week, and how to build a taper that does not collapse in month 3.
Three properties stack against you. Paroxetine clears fast, it has no active metabolite to cushion the drop, and it inhibits its own metabolism through the CYP2D6 enzyme, so blood levels fall unpredictably once you get to smaller doses.
A 2019 Lancet Psychiatry review by Horowitz and Taylor on tapering antidepressants identified paroxetine and venlafaxine as the two agents with the highest withdrawal incidence. Paroxetine is also strongly anticholinergic compared with other SSRIs, which adds a second withdrawal layer: cholinergic rebound, felt as nausea, sweating, cramping, and vivid dreams.
The fast clearance matters more than people expect. With a 21 hour half-life, missing a single dose drops blood levels enough to trigger symptoms by the next evening. That is also why brain zaps, the electrical jolt sensation, are reported more with paroxetine than with any other antidepressant.
Compare that to Prozac (fluoxetine), which has a half-life of 4 to 6 days plus an active metabolite lasting up to 16 days. Fluoxetine tapers itself. Paroxetine does the opposite.
The FDA prescribing label for paroxetine acknowledges discontinuation symptoms and advises gradual reduction, but gives no schedule. That gap is where most patients get hurt.
Bottom line: Paxil is hard to quit because it leaves your body fast, has nothing to soften the fall, and adds anticholinergic rebound on top of serotonergic withdrawal.
Withdrawal from paroxetine starts within 1 to 3 days of a dose reduction, faster than almost any other antidepressant. The NICE guideline NG222 on medicines associated with dependence or withdrawal symptoms states plainly that withdrawal can be severe and last for months, which reversed decades of "mild and self-limiting" messaging.
Symptoms fall into four groups. Neurological effects include brain zaps, dizziness, and balance problems. Physical effects include nausea, sweating, flu-like aching, and headaches. Emotional effects include irritability, sudden crying, anxiety surges, and anger that feels chemical rather than situational. Sensory effects include light sensitivity, tinnitus, and skin that hurts to touch.
Here is the typical arc after a reduction that was too large:
| Time since reduction | What most people report | | | | Day 1 to 3 | Brain zaps, dizziness, nausea begin | | Day 4 to 10 | Peak intensity, sleep breaks up, anxiety spikes | | Week 2 to 4 | Gradual settling if the drop was tolerable | | Week 4 to 8 | Symptoms should be gone before the next reduction | | Month 3+ | Persistent symptoms mean the taper is moving too fast |
That last row is the diagnostic one. If you are still symptomatic 8 weeks after a cut, the cut was too big. Hold at your current dose until you are stable, then reduce by a smaller percentage next time.
Bottom line: paroxetine withdrawal starts in days, peaks in the first 2 weeks, and should resolve before your next reduction. Ongoing symptoms mean slow down, not push through.
Withdrawal and relapse differ in timing, symptom mix, and response to dose. Depression relapse builds over weeks and mirrors your original episode. Withdrawal starts within days of a dose change and includes physical symptoms you never had before, like brain zaps, vertigo, and electric shock sensations.
The clearest test is reinstatement. Withdrawal symptoms improve within 1 to 3 days of going back to the prior dose. A genuine depressive relapse does not respond that fast.
Many patients are told the return of symptoms proves they need the drug for life. That claim confuses a physiological adaptation with an underlying illness. Your brain downregulated serotonin signaling over years of exposure, and removing the drug faster than it can readjust produces symptoms whether or not you were ever depressed.
Patient-run communities documented this long before the literature caught up. Surviving Antidepressants, which has collected SSRI tapering reports since 2011, was describing protracted paroxetine withdrawal a decade before NICE revised its guidance.
Bottom line: symptoms starting within days of a dose change, including physical sensations you have never had, are withdrawal, not relapse.
Hyperbolic tapering is reducing your dose by a fixed percentage of your current dose rather than a fixed number of milligrams, because the relationship between dose and serotonin transporter occupancy is curved, not straight.
At standard doses, paroxetine already saturates roughly 80% of serotonin transporters. Cutting from a high dose to a moderate one barely changes occupancy, which is why the first reductions often feel easy. The steep part of the curve sits at the very bottom. The final small fraction of your dose can carry more receptor effect than every reduction before it combined.
This explains the pattern people describe constantly: three easy reductions, then a wall. Nothing changed about your resilience. You reached the steep part of the curve.
The Maudsley Deprescribing Guidelines, the first prescribing manual built around hyperbolic reduction, formalized this approach for antidepressants, benzodiazepines, and other psychotropics.
Practically, each reduction should be about 10% of whatever you are currently taking, so the absolute size of each cut shrinks as you go. The tail end of the taper takes the longest, and it needs formulations that allow small reductions: liquid paroxetine suspension or compounded doses rather than split tablets.
Bottom line: reduce by a percentage of your current dose, never a fixed milligram step, and expect the last stretch to take the most time.
The usual clinical advice, halving the dose for 2 weeks then stopping, fails because it applies linear reduction to a hyperbolic system. Each cut removes a progressively larger share of receptor occupancy while your nervous system gets progressively less time to adapt.
There is also a research problem. Withdrawal was studied mostly in short discontinuation trials lasting weeks, in people who had taken the drug for weeks. Most real patients have been on paroxetine for years. A systematic review of antidepressant withdrawal incidence and duration indexed in PubMed found rates far above the "mild, resolves in a week" figure that shaped prescribing culture.
When a fast taper fails, the failure is usually misread. The patient returns in crisis, the symptoms get labeled relapse, and the dose goes back up permanently. That sequence turns a 6 month taper into another 5 years of exposure.
If you have already crashed from a fast taper, that is recoverable. Reinstating a portion of the prior dose, stabilizing for several weeks, then restarting at 10% reductions works for most people. Reinstatement is most reliable within the first few months after stopping.
Bottom line: the standard taper fails for pharmacological reasons, not personal ones, and a failed attempt does not mean you cannot come off paroxetine.
Start from stability, not urgency. Do not begin tapering during an acute life crisis, a move, or a job loss, because you need a stable baseline to tell withdrawal apart from ordinary stress.
Track symptoms daily before you touch the dose. Two weeks of baseline data makes every later decision easier, since you will know which symptoms are new. Our symptom tracking journal exists for this, and a plain notebook works too. Rate sleep, anxiety, dizziness, and mood on a 0 to 10 scale.
Then reduce by roughly 10% of current dose and hold for 4 weeks minimum. If you are fully stable at the end of that hold, reduce again. If not, hold longer. Holding is not failure or lost time. It is the mechanism by which the taper works.
Solve the measurement problem early. Paroxetine tablets do not split into small enough pieces for the tail end of a taper. Liquid suspension, which is commercially available, lets you measure precise small doses with an oral syringe. Compounding pharmacies are the other route. Sorting this out at the start prevents a forced large jump later.
Finding a prescriber who will support a long taper matters more than any other single factor. Our directory of deprescribing-informed clinicians is one starting point, and Deprescribing.org, which publishes evidence-based deprescribing algorithms, has material you can bring to an appointment.
Bottom line: baseline tracking, 10% reductions of current dose, 4 week holds, liquid dosing for the tail, and a prescriber who will write for it.
Acute symptoms after each reduction last 1 to 4 weeks. The full taper typically takes 6 months to 2 years depending on dose, years of use, and sensitivity. A minority experience protracted symptoms lasting longer, which improve gradually over months.
No. Stopping paroxetine abruptly produces the highest withdrawal rates of any SSRI and risks severe symptoms including akathisia, an intense internal restlessness. If you already stopped abruptly and feel terrible, reinstating a portion of your prior dose and tapering from stability is the standard corrective step.
It is a starting point, not a rule. Some people tolerate faster, and many need slower, especially below the halfway mark. Your symptoms after each reduction tell you the right pace better than any schedule does.
Brain zaps track closely with short half-life drugs. Paroxetine clears in about 21 hours with no active metabolite, so levels swing sharply between doses and after reductions. They are not dangerous, and they resolve as levels stabilize.
Some people experience persistent sexual dysfunction after stopping SSRIs, a condition documented by the PSSD Network, which tracks post-SSRI sexual dysfunction. It is uncommon but real, and it is one reason informed consent before starting these drugs matters. Our informed consent generator helps you get those questions answered in writing.
Paroxetine asks more of you than other SSRIs because of how it moves through the body, not because of anything about you. A taper built on percentage reductions, long holds, and accurate dose measurement works. A taper built on a 4 week calendar usually does not.
If you are tapering now, read the full Paxil (paroxetine) drug profile for dosing forms and interaction details, compare it with the Zoloft (sertraline) profile if you are weighing class differences, and talk with people at the same stage in the taper.community forums. Being told your symptoms are real by someone who has had them is worth a great deal at 2am.
<script type="application/ld+json"> { "@context": "https://schema.org", "@type": ["Article", "MedicalWebPage"], "headline": "How to Taper Off Paxil (Paroxetine): One of the Hardest SSRIs to Quit", "datePublished": "2026-07-20", "dateModified": "2026-07-20", "author": { "@type": "Person", "name": "Based Psychiatrist", "url": "https://taper.community/about" }, "publisher": { "@type": "Organization", "name": "Taper Community", "url": "https://taper.community" }, "about": { "@type": "Drug", "name": "paroxetine", "alternateName": "Paxil" }, "medicalAudience": { "@type": "MedicalAudience", "audienceType": "Patient" }, "specialty": "Psychiatry", "citation": [ { "@type": "ScholarlyArticle", "name": "Tapering of SSRI treatment to mitigate withdrawal symptoms", "url": "https://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366(19)30032-X/fulltext", "author": "Horowitz MA, Taylor D", "datePublished": "2019" }, { "@type": "WebPage", "name": "NICE NG222: Medicines associated with dependence or withdrawal symptoms", "url": "https://www.nice.org.uk/guidance/ng222", "datePublished": "2022" }, { "@type": "WebPage", "name": "FDA prescribing information for paroxetine (Paxil)", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020031s067,020710s031.pdf", "datePublished": "2012" }, { "@type": "ScholarlyArticle", "name": "A systematic review into the incidence, severity and duration of antidepressant withdrawal effects", "url": "https://pubmed.ncbi.nlm.nih.gov/30292574/", "author": "Davies J, Read J", "datePublished": "2019" }, { "@type": "WebPage", "name": "Maudsley Deprescribing Guidelines", "url": "https://www.maudsleyprescribing.com/" }, { "@type": "WebPage", "name": "Surviving Antidepressants: peer support for psychiatric drug tapering", "url": "https://www.survivingantidepressants.org/" }, { "@type": "WebPage", "name": "Deprescribing.org evidence-based deprescribing algorithms", "url": "https://deprescribing.org/" }, { "@type": "WebPage", "name": "PSSD Network: post-SSRI sexual dysfunction", "url": "https://www.pssdnetwork.org/" } ], "mainEntity": { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "How long does paroxetine withdrawal last?", "acceptedAnswer": { "@type": "Answer", "text": "Acute symptoms after each reduction last 1 to 4 weeks. A full Paxil taper typically takes 6 months to 2 years depending on dose, duration of use, and individual sensitivity." } }, { "@type": "Question", "name": "Can I just stop Paxil cold turkey?", "acceptedAnswer": { "@type": "Answer", "text": "No. Paroxetine produces the highest abrupt-discontinuation withdrawal rates of any SSRI. If you already stopped abruptly, reinstating part of the prior dose and tapering from stability is the standard corrective step." } }, { "@type": "Question", "name": "Is 10% every 4 weeks a rule for tapering Paxil?", "acceptedAnswer": { "@type": "Answer", "text": "It is a starting point, not a rule. Many people need slower reductions in the lower dose range. Symptoms after each reduction are the better guide." } }, { "@type": "Question", "name": "Why do brain zaps happen with Paxil?", "acceptedAnswer": { "@type": "Answer", "text": "Paroxetine has a roughly 21 hour half-life and no active metabolite, so levels swing sharply between doses and after reductions. Brain zaps are not dangerous and resolve as levels stabilize." } }, { "@type": "Question", "name": "Does long-term Paxil use cause lasting side effects?", "acceptedAnswer": { "@type": "Answer", "text": "Some people experience persistent sexual dysfunction after stopping SSRIs, known as PSSD. It is uncommon but documented, and is one reason informed consent before starting matters." } } ] } } </script>Medical disclaimer: This article is for information only and is not medical advice. Never change a psychiatric medication dose without support from a prescriber who knows your history. If you are in crisis, contact your local emergency services.